Hidden costs of PANS: new study reveals financial toll of IVIG treatment

NCT ID NCT06818656

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study surveyed 65 U.S. families to understand the economic and quality-of-life impact of IVIG treatment for PANS/PANDAS. Researchers asked about medical visits, insurance, work absences, and children's school attendance. The goal is to shed light on the hidden costs of treating—or not treating—this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
IVIG (intravenous immunoglobulin)
What this could lead to
If successful, this research could highlight the economic and social burden of PANS/PANDAS and support better insurance coverage or treatment access.
What could go wrong
This is a small, completed survey study—not a treatment trial. It measures costs and quality of life, not whether IVIG works. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANDAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brain Inflammation Collaborative

    Delafield, Wisconsin, 53018, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.